[SEOUL, South Korea – November 5, 2025]
ERBELLA, a premium medical aesthetics brand under USCarePharm, successfully participated in KOREADERMA 2025, held from October 31 to November 2 at COEX, Magok, Seoul.
During the three-day event, the company showcased its flagship product ERBELLA AQ along with its eight-product skin booster lineup, drawing significant attention from domestic and international aesthetic and dermatology professionals.

A Premier Platform for Global K-Aesthetics Innovation

KOREADERMA is Asia’s leading international dermatology symposium, serving as a major platform that brings together the latest advancements in K-Medical and K-Beauty.
This year’s conference gathered experts from across the globe, offering an opportunity to experience the technological excellence and global competitiveness of Korea’s medical aesthetics industry.

ERBELLA AQ: Redefining Injectable Innovation

At its exhibition booth, ERBELLA introduced the brand’s unique technological strengths and product portfolio to global medical professionals and buyers.
The brand’s highlight, ERBELLA AQ, received strong interest from attending experts.

ERBELLA AQ is a liquid-type (suspension) formulation that combines Poly-L-Lactic Acid (PLLA) with cross-linked Hyaluronic Acid (HA) — a ready-to-use product requiring no reconstitution process.

This consumer-centric formulation enhances practitioner convenience while delivering immediate, natural volumizing effects post-procedure.
Cross-linked HA provides instant hydration and plumping, while PLLA gradually stimulates collagen synthesis, achieving a natural and long-lasting volumizing effect.

Thanks to the stability of its liquid suspension, ERBELLA AQ has also been recognized for its low risk of nodules or granulomas, ensuring superior safety compared to traditional formulations.

Comprehensive Skin Booster Lineup Unveiled

Alongside ERBELLA AQ, the brand also unveiled its 8-type skin booster lineup, offering customized programs targeting various skin concerns — including hydration, radiance, elasticity, antioxidant protection, and regeneration.
Each formula is designed for flexible combination and personalization based on the patient’s skin condition and treatment goals.

Through this presentation, ERBELLA reinforced its dual-track strategy:

“Natural Volume with AQ, Skin Quality Improvement with Skin Boosters,”
solidifying its position as a total aesthetic solution brand.

“ERBELLA AQ and our skin booster lineup deliver two key values — natural volume and improved skin texture,”
said an ERBELLA representative.
“Through KOREADERMA 2025, we once again confirmed the strong global competitiveness of Korea’s aesthetic and medical technology.”

Reporter: Kim Mi-kyung, Medical Today